Rockwell Medical, Inc. to Present at Biotech Showcase™ 2019
December 21 2018 - 7:03AM
Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the
"Company") today announced that Stuart Paul, Chief Executive
Officer, will present at Biotech Showcase™ 2019 during the J.P.
Morgan Annual Healthcare Conference as follows:
Date: |
Monday, January 7,
2019 |
|
|
Time: |
3:00 p.m. Pacific
Standard Time |
|
|
Location: |
Hilton San Francisco
Union Square Hotel, San Francisco, CA |
|
|
Track: |
Franciscan A (Ballroom
Level) |
|
|
Webcast: |
https://event.webcasts.com/starthere.jsp?ei=1226087&tp_key=a344b24141 |
The presentation will be webcast live at the aforementioned
time, and archived for 30 days thereafter, via the Company’s
website at www.rockwellmed.com, under the Investors section.
To schedule a one-on-one meeting with management, please contact
Lisa Wilson at lwilson@insitecony.com.
Biotech Showcase™ is an investor conference devoted to providing
private and public biotechnology and life sciences companies with
an opportunity to present to, and meet with, investors and
pharmaceutical executives in one place during the course of one of
the industry's largest annual healthcare investor conferences, J.P.
Morgan Annual Healthcare Conference.
About Rockwell Medical, Inc.Rockwell Medical is
a biopharmaceutical company targeting end-stage renal disease
(ESRD) and chronic kidney disease (CKD). Rockwell Medical's
exclusive renal drug therapies support disease management
initiatives to improve the quality of life and care of dialysis
patients and are intended to deliver safe and effective therapy,
while decreasing drug administration costs and improving patient
convenience. Rockwell Medical's anemia drug Triferic is the only
FDA-approved product indicated for iron replacement and maintenance
of hemoglobin in hemodialysis patients. Rockwell's FDA approved
generic drug Calcitriol (active vitamin D) is for treating
secondary hyperparathyroidism in patients undergoing chronic renal
dialysis. Rockwell Medical is also an established manufacturer,
supplier and leader in delivering high-quality hemodialysis
concentrates/dialysates (used to maintain human life by removing
toxins and replacing critical nutrients in the dialysis patient's
bloodstream) to dialysis providers and distributors in the U.S. and
abroad. Please visit www.rockwellmed.com for more information.
Forward-Looking StatementCertain statements in
this press release may constitute "forward-looking statements"
within the meaning of the federal securities laws, including, but
not limited to, Rockwell's intention to bring to market Triferic,
IV Triferic and Calcitriol. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "could," "plan," "potential," "predict," "forecast,"
"project," "plan", "intend" or similar expressions, or statements
regarding intent, belief, or current expectations, are
forward-looking statements. While Rockwell believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward-looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties
(including, without limitation, those set forth in Rockwell's SEC
filings), many of which are beyond our control and subject to
change. Actual results could be materially different. Risks and
uncertainties include: statements about the timing and success of
our planned NDA submission for IV Triferic; the potential market
opportunity for IV Triferic and other Rockwell products; pricing
and reimbursement status for IV Triferic, Triferic and other
Rockwell products, including eligibility for add-on reimbursement
under TDAPA; liquidity and capital resources; expected duration of
Rockwell Medical's existing working capital; plans and timing
relating to the planned commercialization of Triferic; and timing
and success of our efforts to renegotiate economic terms of our
concentrate business Rockwell expressly disclaims any obligation to
update or alter any statements whether as a result of new
information, future events or otherwise, except as required by
law.
Contact Investor Relations:Lisa M. Wilson, In-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024